Telomerase expression predicts unfavorable outcome in osteosarcoma

Journal of Clinical Oncology

Volumn 22, Issue 18, 2004, Pages 3790-3797

  Sanders, Robert P ^a   Drissi, Rachid ^a   Billups, Catherine A ^a   Daw, Najat C ^a   Valentine, Marcus B ^a   Dome, Jeffrey S ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MOLECULAR MARKER; TELOMERASE;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; OSTEOSARCOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; ADOLESCENT; ADULT; BIOSYNTHESIS; BONE TUMOR; CHILD; FEMALE; GENETICS; MALE; PATHOLOGY; PREDICTION AND FORECASTING; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SURVIVAL;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; OSTEOSARCOMA; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RNA, MESSENGER; SURVIVAL ANALYSIS; TELOMERASE;

EID: 4644342289     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.03.043     Document Type: Article

References (40)

1. Dome JS, Schwartz CL: Osteosarcoma. Cancer Treat Res 92:215-251, 1997
2. Link MP, Gebhart MC, Meyers PA: Ostecsarcoma, in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology. Philadelphia, PA, Lippincott Williams & Wilkins, 2002, pp 1051-1089
3. Goorin AM, Harris MB, Bernstein M, et al: Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A Pediatric Oncology Group trial. J Clin Oncol 20:426-433, 2002
4. Bacci G, Briccoli A, Ferrari S, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremity: Long-term results of the Rizzoli's 4th protocol. Eur J Cancer 37:2030-2039, 2001
5. Harris MB, Gieser P, Goorin AM, et al: Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group Study. J Clin Oncol 16:3641-3648, 1998
6. Meyers PA, Gorlick R, Heller G, et al: Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16: 2452-2458, 1998
7. Provisor AJ, Ettinger LJ, Nachman JB, et al: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 15:76-84, 1997
8. Gorlick R, Anderson P, Andrulis I, et al: Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: Meeting summary. Clin Cancer Res 9:5442-5453, 2003
9. Ulaner GA, Huang HY, Otero J, et al: Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63:1759-1763, 2003
10. Sotillo-Pineiro E, Sierrasesumaga L, Patino-Garcia A: Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients. Pediatr Res 55:231-235, 2004
11. de Lange T: Protection of mammalian telomeres. Oncogene 21:532-540, 2002
12. Harley CB: Telomere loss: Mitotic clock or genetic time bomb? Mutat Res 256:271-282, 1991
13. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
14. Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994
15. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791, 1997
16. Bryan TM, Englezou A, Dalla-Pozza L, et al: Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3:1271-1274, 1997
17. Scheel C, Schaefer KL, Jauch A, et al: Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene 20:3835-3844, 2001
18. Stewart SA, Hahn WC, O'Connor BF, et al: Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 99:12606-12611, 2002
19. Chang S, Khoo CM, Naylor ML, et al: Telomere-based crisis: Functional differences between telomerase activation and ALT in tumor progression. Genes Dev 17:88-100, 2003
20. Bieche I, Nogues C, Paradis V, et al: Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6:452-459, 2000
21. Dome JS, Chung S, Bergemann T, et al: High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. Cancer Res 59:4301-4307, 1999
22. Kaplan EL, Meier P: Nonparametric estimations from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Kalbfleisch JD, Prentice RL: The statistical analysis of failure time data. New York, Wiley, 1980, pp 163-188
24. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
25. Link MP, Goorin AM, Horowitz M, et al: Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop: 8-14, 1991
26. Meyer WH, Pratt CB, Poquette CA, et al: Carboplatin/ifosfamide window therapy for osteosarcoma: Results of the St Jude Children's Research Hospital OS-91 Trial. J Clin Oncol 19: 171-182, 2001
27. Dome JS, Bockhold CA, Li SM, et al: Telomerase RNA expression as a prognostic marker in patients with favorable histology Wilms tumor. Proc Am Soc Clin Oncol 22:803S, 2004 (abstr 8519)
28. Poremba C, Willenbring H, Hero B, et al: Telomerase activity distinguishes between neuroblastomas with good and poor prognosis. Ann Oncol 10:715-721, 1999
29. Poremba C, Scheel C, Hero B, et al: Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: A molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol 18:2582-2592, 2000
30. Verstovsek S, Manshouri T, Smith FO, et al: Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: Comparison with adult acute myeloid leukemia. Cancer 97:2212-2217, 2003
31. Ohali A, Avigad S, Cohen IJ, et al: Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors. J Clin Oncol 21:3836-3843, 2003
32. Ludwig A, Saretzki G, Holm PS, et al: Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res 61:3053-3061, 2001
33. Kondo Y, Kondo S, Tanaka Y, et al: Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 16:2243-2248, 1998
34. Yuan Z, Mei HD: Inhibition of telomerase activity with hTERT antisense increases the effect of CDDP-induced apoptosis in myeloid leukemia. Hematol J 3:201-205, 2002
35. Misawa M, Tauchi T, Sashida G, et al: Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells. Int J Oncol 21:1087-1092, 2002
36. Perrem K, Colgin LM, Neumann AA, et al: Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol 21:3862-3875, 2001
37. Ford LP, Zou Y, Pongracz K, et al: Telomerase can inhibit the recombination-based pathway of telomere maintenance in human cells. J Biol Chem 276:32198-32203, 2001
38. Grobelny JV, Kulp-McEliece M, Broccoli D: Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway. Hum Mol Genet 10:1953-1961, 2001
39. Cerone MA, Londono-Vallejo JA, Bacchetti S: Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet 10:1945-1952, 2001
40. Hakin-Smith V, Jellinek DA, Levy D, et al: Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 361:836-838, 2003